KEY POINTS
- ARO 04-01/AHMO (DRKS00040575) was a multicenter randomized phase III superiority trial conducted in Germany between 2004 and 2008. It enrolled 364 patients with unresectable stage IVA–IVB squamous cell carcinoma of the oropharynx (58.5%) or hypopharynx (41.5%), classified according to UICC TNM sixth edition. Patients were randomized equally to cisplatin/5-fluorouracil or mitomycin C/5-fluorouracil with identical hyperfractionated accelerated radiotherapy. Median follow-up was 87 months, and overall survival was the primary endpoint.
- Both treatment arms received 72 Gy in 45 fractions over six weeks. Radiotherapy began with 2 Gy once daily for 15 fractions, followed by 1.4 Gy twice daily with at least six hours between fractions. The cisplatin arm received 30 mg/m² weekly for up to six cycles, while the mitomycin arm received 10 mg/m² on days 5 and 36. Both groups received continuous-infusion 5-FU at 600 mg/m²/day on days 1–5. Treatment used sequential shrinking fields with 3D conformal RT or, during later years, IMRT.
- Cisplatin/5-FU did not significantly improve the primary overall survival endpoint. Ten-year OS was 23.3% with cisplatin/5-FU versus 18.0% with mitomycin/5-FU, corresponding to an absolute difference of 5.3 percentage points. The treatment hazard ratio was 0.89 (95% CI 0.69–1.15; log-rank p=0.418). Although the observed survival rate numerically favored cisplatin, the superiority hypothesis was not demonstrated. Importantly, failure to establish superiority does not prove equivalence or noninferiority.
- Exploratory competing-risk analyses favored cisplatin for distant disease control. Five-year cumulative distant metastasis incidence was 25.9% with cisplatin versus 36.1% with mitomycin, corresponding to a subdistribution HR of 0.66 (95% CI 0.45–0.96; p=0.031). Cumulative progression incidence was 45.6% versus 56.3% (sHR 0.73, 95% CI 0.55–0.98; p=0.037). However, these competing-risk analyses were performed post hoc, and conventional Kaplan–Meier comparisons were not significant. Sensitivity analyses counting death as an event also showed no significant differences.
- Locoregional control was similar between treatment strategies. At ten years, local control was 61.5% versus 64.1%, regional control 75.3% versus 72.5%, and locoregional control 54.2% versus 53.5% for cisplatin/5-FU and mitomycin/5-FU, respectively. None of these comparisons reached statistical significance. Long-term differences between oropharyngeal and hypopharyngeal subgroups were also not significant, although the trial predates routine HPV-based classification.
- Cisplatin was associated with greater renal toxicity and a higher recorded adverse-event burden. Mean serum creatinine during treatment was 0.87 ± 0.28 mg/dL with cisplatin versus 0.76 ± 0.18 mg/dL with mitomycin (p<0.001). Recorded adverse or serious adverse events occurred in 24.2% versus 15.4% (p=0.048), respectively. Acute grade 3 mucositis, dysphagia, and dermatitis were common in both arms, without significant treatment-group differences. Grade ≥2 thrombocytopenia occurred in 6.7% versus 2.8%, respectively, and did not significantly favor either regimen.
- Treatment completion was high, but the historical protocol limits current applicability. Radiotherapy was completed within the planned treatment window in 95% of cisplatin patients and 96% of mitomycin patients. In the cisplatin arm, 72% received at least five of six weekly doses, while 86% of mitomycin patients received both planned doses. The trial used a maximum cisplatin exposure of 180 mg/m², a historical accelerated RT regimen, and staging without routine HPV or modern molecular characterization. Consequently, its results cannot establish that mitomycin/5-FU is equivalent to contemporary cisplatin-based IMRT regimens.
CLINICAL TAKEAWAY
Mitomycin C/5-FU achieved similar observed long-term overall survival to cisplatin/5-FU when combined with historical hyperfractionated accelerated radiotherapy, while cisplatin produced more renal toxicity and exploratory improvements in distant disease control. These findings provide randomized evidence supporting further consideration of mitomycin-based treatment when cisplatin is unsuitable, but do not establish noninferiority or justify replacing cisplatin in eligible patients receiving contemporary chemoradiotherapy.
SOURCE
International Journal of Radiation Oncology, Biology, Physics